Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher24/7 Wall Street • 10/20/26
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisCNBC • 10/20/26
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/10/26
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.The Motley Fool • 10/09/26
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge cautionMarket Watch • 10/08/26
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A PremiumSeeking Alpha • 10/08/26
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 10/07/26
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Zacks Investment Research • 10/07/26
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?The Motley Fool • 10/07/26
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?Zacks Investment Research • 10/06/26
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/06/26
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkZacks Investment Research • 10/05/26